The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Bayer; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; Lilly
 
Hyun Cheol Chung
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Celltrion; Gloria Biosciences; Lilly; Merck Serono; MSD; Quintiles; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Foundation medicine; Lilly; Merck Serono
Research Funding - Amgen; Beigene; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Taiho Pharmaceutical
 
Young Hyuck Im
No Relationships to Disclose
 
Chia Jui Yen
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose
 
ZheZhen Li
Employment - AstraZeneca; BeiGene
Stock and Other Ownership Interests - BeiGene
 
Xin Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Jin Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Huiyan Li
Employment - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Yoon-Koo Kang
Consulting or Advisory Role - ALX Oncology; Amgen; Astellas Pharma; Bristol-Myers Squibb; DAEHWA Pharmaceutical; Macrogenics; Merck Serono; Novartis; Ono Pharmaceutical; Surface Oncology; Taiho Pharmaceutical; Zymeworks